
Please try another search
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Mary T. Szela | 58 | 2014 | Independent Director |
Dennis M. Lanfear | 66 | 2010 | Chairman, President & CEO |
Michael Ryan | - | 2023 | Director |
Ali J. Satvat | 47 | 2014 | Independent Director |
Mats L. Wahlstrom | 71 | 2012 | Lead Independent Director |
James M. Daly | 63 | 2016 | Member of Strategic Advisory Board |
Thomas Graeber | - | 2021 | Member of Scientific Advisory Board |
Jill O’Donnell-Tormey | 69 | 2022 | Independent Director |
Carl F. Ware | - | 2021 | Member of Scientific Advisory Board |
Daniel G. Welch | 67 | 2023 | Member of Strategic Advisory Board |
Charles W. Newton | 54 | 2022 | Independent Director |
Taofeek K. Owonikoko | - | 2022 | Member of Scientific Advisory Board |
Lee N. Newcomer | 73 | 2022 | Independent Director |
Rita A. Karachun | 61 | 2024 | Independent Director |
Michael Lee Ryan | 70 | 2023 | Independent Director |
John Wherry | - | - | Member of Scientific Advisory Board |
Alexander Rudensky | - | - | Member of Scientific Advisory Board |
Christopher A. Hunter | - | 2023 | Member of Scientific Advisory Board |
John Stagg | - | 2023 | Member of Scientific Advisory Board |
Georgia L. Erbez | 58 | 2024 | Independent Director |
J. Leighton Read | 74 | 2023 | Member of Strategic Advisory Board |
Theresa M. Lavallee | 59 | 2022 | Chief Development Officer & Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review